Washington University/ Siteman Cancer Center Lead Academic Site

华盛顿大学/斯特曼癌症中心领导学术网站

• 批准号: 8845177
• 负责人: NANCY L BARTLETT
• 金额: $ 154.93万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-02 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8845177
• 关键词: American College of Radiology Imaging Network; American College of Surgeons Oncology Group; Area; Cancer Center; Cancer and Leukemia Group B; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Communication; Comprehensive Cancer Center; Conduct Clinical Trials; Correlative Study; Development; Diagnostic; Diagnostic Neoplasm Staging; Disease; Eastern Cooperative Oncology Group; Enrollment; Fostering; Goals; Gynecologic Oncology; Gynecologic Oncology Group; Illinois; Image; Institution; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Medical Oncology; Mentors; Mentorship; Mission; Missouri; Modality; Patients; Physicians; Play; Principal Investigator; Prognostic Marker; Radiation Oncology; Radiation Therapy Oncology Group; Radiology Specialty; Recording of previous events; Research; Research Personnel; Site; Specialist; Therapeutic Trials; Thoracic Oncology; Translational Research; Universities; Washington; Work; anticancer research; biobank; cancer therapy; collaborative environment; design; experience; improved; leukemia/lymphoma; malignant breast neoplasm; member; metropolitan; oncology; operation; professor; programs; public health relevance; tool

DESCRIPTION (provided by applicant): The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) Lead Academic Site is to create a supportive environment that will foster 1) scientific leadership and mentorship, 2) development of cooperative group clinical trials, 3) substantial accrual to clinical trials across the entire NCTN and 4) exceptional conduct of clinical trials. Investigators at WU/SCC are committed to work to enhance the research goals of the NCTN Program and to enroll patients to NCTN trials across the Network. WU/SCC investigators have a long history of enthusiastic participation in the cooperative groups including ACOSOG, ACRIN, CALGB, GOG, and RTOG and will continue to play key roles in the newly merged groups including the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 U10 Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Bryan F. Meyers, MD, MPH (Professor, Thoracic Oncology), Jeff M. Michalski, MD, MBA (Professor, Radiation Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology) and Barry A. Siegel, MD (Professor, Radiology). All members of the senior leadership team have extensive clinical trial experience, including many years of cooperative group involvement, and are committed to providing guidance for an institution-wide cooperative group NCTN UI0. WU/SCC is consistently among the top accruing institutions in each of the cooperative groups with outstanding accrual across many disease sites. Between January 2007 and June 2012, WU/SCC accrued 1633 patients to cooperative group therapeutic trials, an average of 297 patients per year for the last 5.5 years (171 ACOSOG, 1024 CALGB/Alliance, 156 GOG, and 282 RTOG). During this same interval, 727 patients had biospecimens collected and 101 patients were accrued to advanced imaging studies through ACRIN. WU/SCC investigators are highly motivated to contribute to the scientific mission of the NCTN, particularly in the areas of breast cancer, gynecological oncology, thoracic oncology, Gl oncology, GU oncology, leukemia, and lymphoma. Strong translational science in breast cancer, lung cancer, and AML at WU/SCC, along with large institutional biorepositories, will provide many opportunities for unique contributions to correlative studies associated with cooperative group therapeutic trials. This institution-wide UIO will facilitate enhanced communication and collaboration among disease site and modality specialists and improve our potential for contributions to the NCTN operation.

描述(由申请者提供)：建议的华盛顿大学/西特曼癌症中心(WU/SCC)主要学术站点的基本目标是创造一个支持性的环境，将培养1)科学领导和指导，2)合作小组临床试验的发展，3)整个NCTN的临床试验的实质性收益 以及4)特殊的临床试验。WU/SCC的研究人员致力于提高NCTN计划的研究目标，并在整个网络中招募患者参加NCTN试验。吴/SCC调查人员长期以来一直积极参与ACOSOG、ACRIN、CALGB、GOG和RTOG等合作小组，并将继续在新合并的小组中发挥关键作用，包括肿瘤学临床试验联盟、ECOG-ACRIN癌症研究小组和NRG肿瘤学。Wu/SCC将有5名U10首席调查员，由高级领导团队组成，包括医学博士南希·L·巴特利特(医学肿瘤学教授)、医学博士布莱恩·F·迈耶斯(医学博士，公共卫生硕士)、杰夫·M·米哈尔斯基(医学博士，放射肿瘤学教授)、MBA(放射肿瘤学教授)、大卫·G·穆奇医学博士(妇科肿瘤学教授)和医学博士巴里·A·西格尔(放射学教授)。高级领导团队的所有成员都拥有丰富的临床试验经验，包括多年的合作小组参与，并致力于为机构范围的合作小组NCTN UI0提供指导。在每个合作小组中，吴/SCC一直是最大的应计机构之一，在许多疾病地点都有突出的应计。2007年1月至2012年6月，WU/SCC积累了1633名患者参加合作小组治疗试验，过去5.5年平均每年297名患者(ACOSOG 171例，CALGB/Alliance 1024例，GOG 156例，RTOG 282例)。在同一时间段，727名患者接受了生物显微镜检查，101名患者通过ACRIN进行了高级影像研究。WU/SCC调查人员非常有动力为NCTN的科学使命做出贡献，特别是在乳腺癌、妇科肿瘤学、胸部肿瘤学、Gl肿瘤学、口腔肿瘤学、白血病和淋巴瘤领域。吴/SCC在乳腺癌、肺癌和AML方面的强大翻译科学，以及大型机构生物库，将为与合作小组治疗试验相关的相关研究提供许多独特贡献的机会。这一机构范围内的UIO将促进疾病现场和医疗保健专家之间加强沟通和合作，并提高我们为NCTN行动做出贡献的潜力。